United States Short Bowel Syndrome Market to reach US$ 7.93 Billion by 2033

short bowel syndrome market was valued at US$ 1.39 Billion in 2023, and the market size reached US$ 1.64 Billion in 2024 and is expected to reach US$ 7.93 Billion by 2033, growing at a CAGR of 19.3% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/short-bowel-syndrome-market?kb

United States: Recent Industry Developments

✅ November 2025: Ironwood Pharmaceuticals advanced Phase 3 trials for apraglutide, aiming to improve intestinal absorption and reduce parenteral nutrition dependency.

✅ September 2025: FDA approved new guidelines facilitating faster review of SBS therapies with improved safety profiles.

✅ August 2025: Biotech startups focused on microbiome modulation therapies targeting SBS patient outcomes.

GCC: Recent Industry Developments

✅ October 2025: GCC healthcare providers expanded specialized intestinal rehabilitation programs supported by government health initiatives.

✅ August 2025: Collaboration between regional hospitals and pharmaceutical companies enhanced access to novel SBS treatments.

✅ July 2025: Clinical research centers in UAE initiated pilot studies on novel peptide-based therapies for SBS management.

MENA: Recent Industry Developments

✅ September 2025: Increased awareness campaigns across MENA improved diagnosis rates and early intervention for SBS patients.

✅ July 2025: Regional healthcare systems invested in multidisciplinary care models incorporating nutrition and surgical options.

✅ June 2025: Partnerships between MENA governments and international biopharma companies aimed at expanding SBS treatment access.

Major Growing Players:

Takeda Pharmaceutical Company Limited, OxThera, and Nutricia North America

Key Developments:

1. In April 2025, Ironwood Pharmaceuticals disclosed that the FDA has requested a confirmatory Phase 3 trial for apraglutide targeting patients with short bowel syndrome with intestinal failure (SBS-IF) who depend on parenteral support. While advancing this development, Ironwood has partnered with Goldman Sachs to evaluate strategic options designed to maximize shareholder value.

2. Earlier, in January 2025, Ironwood Pharmaceuticals announced a renewed strategic focus on advancing apraglutide for SBS patients reliant on parenteral nutrition. To support this shift and drive long-term growth, the company plans to reduce its workforce by approximately 50%, optimizing resources for future success.

Forecast Projection:

The Global Short bowl Syndrome Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Global Short bowl Syndrome Market report is built on solid intelligence - powered by both primary and secondary research. Our analysts have deep-dived into every factor that can influence your business roadmap, including government regulations, competitive landscape, tech innovations, historical market behavior, upcoming breakthroughs, adjacent industry trends, market volatility, growth prospects, and potential risks.

Government Regulations

FDA:

1. CRL for glepaglutide (Zealand, Dec 2024): Insufficient efficacy/safety evidence at to-be-marketed dose; Phase III (EASE-5) starts H2 2025 for US resubmission.​

2. Apraglutide (Ironwood): FDA alignment Q4 2025; Phase III H1 2026.​
EMA: Zealand submitted MAA for glepaglutide (Jun 2025); Gattex/Revestive (teduglutide) approved EU since 2012.​

3. Pediatric/Orphan: FDA ODD/Rare Pediatric for sonefpeglutide/HM15912; ESPGHAN 2025 guidelines emphasize multidisciplinary SBS-IF management

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=short-bowel-syndrome-market?kb

Key Segments:

By Drug Class: (GLP-2, Growth Hormone, Glutamine, Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: sets the stage by defining the full scope of the report and delivering an executive summary of key market segments across regions, product types, and applications. It provides a comprehensive snapshot of current market sizes and reveals future growth potential, offering a clear vision of how the market will evolve in the short, mid, and long term.

Chapter 2: uncovers critical insights and highlights the most impactful emerging trends shaping the Short bowl Syndrome market's future - essential knowledge for investors and strategists looking to stay ahead.

Chapter 3: dives deep into the competitive landscape, delivering an in-depth analysis of Short bowl Syndrome manufacturers. It covers market share dynamics, strategic developments, and the latest mergers and acquisitions that are redefining the industry.

Chapter 4: profiles the market's leading players, offering detailed views of their revenue streams, profit margins, product portfolios, and recent innovations - arming you with the intel to benchmark and strategize effectively.

Chapters 5 & 6: break down revenue performance by region and country, providing a quantitative analysis that spotlights growth hotspots, development prospects, and the unique opportunities each market offers across the globe.

Chapter 7: explores market segmentation by type, revealing the size and untapped potential of each segment - guiding you toward lucrative "blue ocean" opportunities that competitors may have overlooked.

Chapter 8: analyzes the market by application, evaluating downstream sectors with the highest growth potential and identifying promising areas for expansion and investment.

Chapter 9: maps the entire industry supply chain, tracing upstream suppliers to downstream distributors, giving you full visibility into critical business linkages and value drivers.

Chapter 10: wraps up with a powerful summary of the report's key findings and strategic takeaways, delivering the must-know insights every industry stakeholder needs to make confident, forward-looking decisions.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/short-bowel-syndrome-market?kb

FAQ's

Q1: How fast Short bowl Syndrome Market Growing?

A: The Short bowl Syndrome Market was valued at US$ 1.39 Billion in 2023 and is on track for explosive expansion, projected to hit US$ 7.93 Billion by 2033

Q2: How fast is the Short bowl Syndrome Market growing?

A: The Market is set to surge with an impressive CAGR of 19.3% between 2025 and 2032

Have Detailed Enquiry of This Report @ https://www.datamintelligence.com/enquiry/short-bowel-syndrome-market?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.